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Abstract

Key Points

IMPORTANCE Despite more widely accessible combination antiretroviral therapy (cART), HIV-1
infection remains a global public health challenge. Even in treated patients with chronic HIV
infection, neurocognitive impairment often persists, affecting quality of life. Identifying the
neuroanatomical pathways associated with infection in vivo may delineate the neuropathologic
processes underlying these deficits. However, published neuroimaging findings from relatively small,
heterogeneous cohorts are inconsistent, limiting the generalizability of the conclusions drawn
to date.

Question Are HIV plasma markers that
are universally used to monitor immune
function and treatment response
associated with subcortical brain
volumes in clinically and
demographically heterogeneous
HIV-infected individuals?
Findings In this cross-sectional study of

OBJECTIVE To examine structural brain associations with the most commonly collected clinical

1203 HIV-infected adults, lower current

assessments of HIV burden (CD4 T-cell count and viral load), which are generalizable across

CD4+ T-cell counts were associated with

demographically and clinically diverse HIV-infected individuals worldwide.

smaller hippocampal and thalamic

+

volumes independent of treatment

DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study established the HIV Working

status, although in the subset of

Group within the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) consortium

participants not receiving treatment,

to pool and harmonize data from existing HIV neuroimaging studies. In total, data from 1295

they were associated with smaller

HIV-positive adults were contributed from 13 studies across Africa, Asia, Australia, Europe, and North

putamen volumes. Across all

America. Regional and whole brain segmentations were extracted from data sets as contributing

participants, detectable viral load was

studies joined the consortium on a rolling basis from November 1, 2014, to December 31, 2019.

associated with smaller hippocampal
volumes, but in the subset of

MAIN OUTCOMES AND MEASURES Volume estimates for 8 subcortical brain regions were

participants receiving HIV treatment,

extracted from T1-weighted magnetic resonance images to identify associations with blood plasma

detectable viral load was also associated

+

markers of current immunosuppression (CD4 T-cell counts) or detectable plasma viral load (dVL) in
HIV-positive participants. Post hoc sensitivity analyses stratified data by cART status.

with smaller amygdala volumes.
Meaning In a heterogeneous
population of HIV-infected individuals,

RESULTS After quality assurance, data from 1203 HIV-positive individuals (mean [SD] age, 45.7 [11.5]
years; 880 [73.2%] male; 897 [74.6%] taking cART) remained. Lower current CD4+ cell counts were
associated with smaller hippocampal (mean [SE] β = 16.66 [4.72] mm3 per 100 cells/mm3; P < .001)
and thalamic (mean [SE] β = 32.24 [8.96] mm3 per 100 cells/mm3; P < .001) volumes and larger
ventricles (mean [SE] β = −391.50 [122.58] mm3 per 100 cells/mm3; P = .001); in participants not
taking cART, however, lower current CD4+ cell counts were associated with smaller putamen volumes
3

3

(mean [SE] β = 57.34 [18.78] mm per 100 cells/mm ; P = .003). A dVL was associated with smaller
hippocampal volumes (d = −0.17; P = .005); in participants taking cART, dVL was also associated with

volumes of structures in the limbic
system were consistently associated
with plasma markers.

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

smaller amygdala volumes (d = −0.23; P = .004).
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Abstract (continued)

CONCLUSIONS AND RELEVANCE In a large-scale international population of HIV-positive
individuals, volumes of structures in the limbic system were consistently associated with current
plasma markers. Our findings extend beyond the classically implicated regions of the basal ganglia
and may represent a generalizable brain signature of HIV infection in the cART era.
JAMA Network Open. 2021;4(1):e2031190. doi:10.1001/jamanetworkopen.2020.31190

Introduction
In the era of globally accessible combination antiretroviral therapy (cART), morbidity and mortality
rates have markedly decreased for individuals who have contracted HIV-1. HIV-infected individuals
taking cART are now expected to reach near-normal life expectancy.1 However, HIV-related
comorbidities, including symptoms of brain dysfunction, remain common even in treated
HIV-positive individuals.2-4
The prevalence of neurocognitive impairment in HIV-positive populations varies across studies:
in a previous review,5 some reports suggested that cognitive difficulties are present in nearly half of
HIV-positive individuals, but other studies reported that fewer than 20% are affected. This variability
may reflect heterogeneous virus-host dynamics and cART treatment status. Other factors may
include cultural, socioeconomic, and educational variability across clinical settings and geographic
regions5 as well as neuropsychological testing methods, including the use of appropriate normative
data, and the handling of neurologic and psychiatric confounders. Another review3 of studies that
used standard neuropsychological assessments and appropriate normative data found robust
associations between even mild neurocognitive impairment and interference with the capacity to
perform instrumental activities of daily living.
HIV preferentially infects CD4+ T lymphocytes and damages the immune system. CD4+ T-cell
count, a marker of immune function, and HIV viral load (VL) are 2 blood plasma biomarkers routinely
collected from patients with HIV to monitor infection and treatment response. These clinical markers
are also the most consistently available in human studies of HIV, but the degree to which they capture
central nervous system (CNS) injury is not fully understood. Low nadir CD4+ cell counts have been
identified as a factor associated with neurocognitive impairment in the cART era,6 suggesting that
severe immunosuppression may lead to persistent and potentially irreversible brain injury. However,
nadir CD4+ cell counts are frequently self-reported, so they may be unreliable or unknown. The
duration of immunosuppression before recovery and the highest VL may also not be well
documented. Immune restoration and viral suppression are tracked through routine clinical
assessments and may be achieved through modifiable factors, including timely HIV testing and
treatment initiation and adherence. The neurologic implications of maintaining or achieving healthy
targets are therefore important to establish.
Structural neuroimaging provides a promising array of quantitative biomarkers for assessing
CNS function and decline. Neuroimaging biomarkers have provided important noninvasive means to
understand many psychiatric and neurodegenerative diseases and to monitor the effectiveness of
clinical interventions.7 Neuroimaging studies of HIV-positive individuals typically find smaller
subcortical volumes in infected individuals,8 in particular, in structures of the basal ganglia,9-11 and
associations between such structural differences and neurocognitive impairment.12 However, in
studies conducted during the cART era, inconsistencies in the effect sizes and regional distribution of
brain abnormalities associated with CD4+ cell count or VL in HIV-positive individuals have limited the
generalizability of the conclusions drawn to date. These inconsistent findings are likely driven in part
by differences in demographic characteristics, such as age and sex, socioeconomic status, lifestyle
factors, history of trauma, substance use, and clinical heterogeneity of study participants, including
viral suppression, cART timing and adherence, CD4+ cell count range, and other comorbidities. For
instance, a study13 of untreated, chronically infected individuals reported a positive association
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Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User on 02/04/2021

January 15, 2021

2/15

JAMA Network Open | Infectious Diseases

Association of Immunosuppression and Viral Load With Subcortical Brain Volume

between thalamic volumes and current CD4+ T-cell counts, whereas another study14 evaluating a
diverse sample reported negative associations with total subcortical volume (including the
thalamus). However, the effects are not necessarily population specific because studies focusing on
individuals receiving long-term treatment15 and those who are cART naïve16 have both reported no
associations between CD4+ cell count and individual subcortical volumes. Different findings across
studies may also reflect methodologic heterogeneity, including differences in (1) statistical power
with variable sample sizes, in addition to unequal representation of important HIV disease factors
and neurocognitive impairment prevalence; (2) magnetic resonance imaging (MRI) scanners and
image acquisition protocols; and (3) image processing or statistical analysis techniques. By reducing
methodologic variability in image processing, boosting sample size, and assessing a diverse set of
HIV-positive cohorts, a generalizable pattern of HIV-related brain effects may be identified.
The HIV Working Group was established within the Enhancing Neuro Imaging Genetics through
Meta Analysis (ENIGMA) consortium to pool data from neuroimaging studies using harmonized data
analysis pipelines. The working group is a growing international collaboration open to all researchers
investigating the neurologic consequences of HIV infection. This study included active involvement
from investigators of 13 HIV studies across 6 different countries: the US, France, Serbia, Australia,
Thailand, and South Africa (Table 1).17-22 We aimed to investigate structural brain volume associations
with the most commonly collected clinical assessments of HIV burden; we surveyed plasma CD4+

Table 1. Demographic and Clinical Information by Study and Scanning Site
No. (%) of participants

No. (%) of participants

Site

Total, No.

Male,
No. (%)

HIVNC (7 sites), US

Age,
mean (SD) [range], y

Taking cART

Detectable viral
load

CD4+ cell
count,
mean (SD), /μL

CD4+ cell
count
<200/μL

Viral load >400
copies/mL

218

187 (86)

48.5 (8.3) [24-71]

218 (100)

61 (28) [n = 217]

378.0 (231.9)

48 (22)

39 (18) [n = 217]

Site 1: University of California,
San Diego

21

21 (100)

47.6 (5.0) [37-56]

21 (100)

13 (65) [n = 20]

313.7 (328.4)

11 (52)

7 (35) [n = 20]

Site 2: Harbor UCLA Medical
Center, Los Angeles, California

52

42 (81)

46.6 (9.1) [24-70]

52 (100)

8 (15)

350.2 (173.0)

14 (27)

5 (10)

Site 3: Stanford University,
Stanford, California

10

9 (90)

46.4 (10.4) [31-62]

10 (100)

0

313.5 (157.5)

2 (20)

0

Site 4: Colorado

35

34 (97)

49.2 (7.9) [31-66]

35 (100)

14 (40)

446.6 (246.0)

4 (11)

6 (17)

Site 5: Pittsburgh, Pennsylvania

19

18 (95)

49.9 (9.7) [34-71]

19 (100)

4 (21)

438.9 (298.2)

3 (16)

3 (16)

Site 6: Rochester University,
Rochester, New York

41

26 (63)

48.4 (7.7) [26-62]

41 (100)

11 (27)

382.0 (207.8)

6 (15)

7 (17)

Site 7: University of California,
Los Angeles

40

37 (93)

50.7 (8.4) [28-69]

40 (100)

11 (28)

370.7 (224.7)

8 (20)

11 (28)

University of Hawaii,
Honolulu, US17

175

159 (91)

47.6 (10.5) [20-74]

157 (90)

54 (33) [n = 164]

475.2 (281.4)

31 (18)

38 (23) [n = 164]

University of Hawaii,
Honolulu, US18

53

45 (85)

50.9 (8.0) [40-71]

53 (100)

6 (11)

491.1 (208.5)

4 (8)

2 (4)

University of California,
San Francisco, US

50

49 (98)

63.6 (2.5) [60-69]

49 (98)

14 (29) [n = 49]

529.3 (218.5)

0

4 (8) [n = 49]

Brown University, Providence,
Rhode Island, US

79

48 (61)

45.2 (9.5) [23-65]

66 (84)

22 (28)

476.2 (228.8)

7 (9)

21 (27)

University of California,
Los Angeles, US19

12

12 (100)

46.2 (8.5) [26-57]

9 (75)

6 (50)

604.1 (289.1)

1 (8)

4 (33)

University of California,
Los Angeles, US20

51

46 (90)

50.9 (13.2) [24-76]

51 (100)

21 (41)

603.2 (287.7)

2 (4)

9 (18)

University of New South Wales,
New South Wales, Australia21

39

38 (97)

52.8 (8.2) [39-75]

39 (100)

10 (26)

612.5 (269.0)

0

6 (15)

University of New South Wales,
New South Wales, Australia22

68

68 (100)

55.3 (6.7) [44-69]

68 (100)

1 (1)

549.5 (273.6)

5 (7)

1 (1)

SEARCH-011 Consortium,
Bangkok, Thailand

61

26 (43)

34.2 (7.0) [22-56]

0

61 (100)

236.0 (139.0)

25 (41)

61 (100)

University of Cape Town,
South Africa

181

25 (14)

32.4 (5.0) [22-46]

0

148 (97) [n = 152]

225.5 (149.2)

95 (53)

129 (88) [n = 147]

Nice University, Nice, France

155

122 (79)

45.4 (10.0) [22-81]

126 (76)

56 (36)

580.9 (277.6)

11 (7)

39 (25)

University of Novi Sad,
Novi Sad, Serbia

61

55 (90)

44.3 (10.9) [25-66]

61 (100)

10 (16)

616.3 (346.2)

1 (2)

10 (16)

Abbreviations: cART, combination antiretroviral therapy; HIVNC, HIV Neuroimaging Consortium; SEARCH, South East Asian Research Collaboration in HIV.
JAMA Network Open. 2021;4(1):e2031190. doi:10.1001/jamanetworkopen.2020.31190 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User on 02/04/2021

January 15, 2021

3/15

JAMA Network Open | Infectious Diseases

Association of Immunosuppression and Viral Load With Subcortical Brain Volume

T-cell counts and the detectability of viral RNA and assessed their associations with MRI-derived
subcortical brain volumes in HIV-positive individuals. The strength of this large data set is that it is
more representative of many HIV-positive individuals currently living in the cART era (including those
who are not treated, with and without viral suppression) than any single cohort study. Subcortical
regions remain a target of HIV infection; therefore, these structures represent an ideal benchmark
against which the degree of immune recovery, viral suppression, and cART use may be assessed.

Methods
Participants and Clinical Assessments
In this cross-sectional study, T1-weighted brain MRI scans and clinical data from 1295 HIV-positive
adult participants were collected at 19 sites from 13 independent studies. The participating studies
included the multisite HIV Neuroimaging Consortium (7 sites), Brown University, University of
California, San Francisco, 2 groups from the University of Hawaii, and 2 groups from the University of
California, Los Angeles, all in the US; Nice University Hospital in France; the University of Cape Town
in South Africa; 2 groups from the University of South Wales in Australia; University of Novi Sad in
Serbia; and the South East Asian Research Collaboration in HIV 011 study from Thailand. Inclusion and
exclusion criteria for each study are summarized in eTable 1 in the Supplement. Clinical assessments
at the time of MRI included current CD4+ T-cell counts and HIV plasma RNA VL. Each study’s
researchers obtained approval from their local ethics committee or institutional review board;
participants signed an informed consent form at each participating site. All data were deidentified.
This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline.

Image Acquisition, Processing, and Quality Assurance
T1-weighted brain images were acquired at each site on a 3-T or 1.5-T scanner. Acquisition protocols
are detailed in eTable 2 in the Supplement. Intracranial volume was estimated and regional
segmentations performed using FreeSurfer software, version 5.323 on a rolling basis from November
1, 2014, to December 31, 2019, as contributing studies joined the consortium. Volumes were
extracted from 8 regions of interest: thalamus, caudate, putamen, globus pallidus, hippocampus,
amygdala, nucleus accumbens, and lateral ventricles. Because no lateralized effects were
hypothesized, the mean of the left and right volumes for each region of interest was evaluated.
Volume extraction and quality control were completed by each respective site using the publicly
available protocol under the heading ENIGMA Subcortical Segmentation Protocols for Disease
Working Groups (http://enigma.ini.usc.edu/protocols/imaging-protocols). Participants excluded because
of missing or poor quality data are summarized in eTable 3 in the Supplement. Quality assurance also
included a feasibility study to ensure that the pooled sample was able to capture known negative
associations between brain volume and age (eMethods and eResults in the Supplement).

Statistical Analysis
Associations Between Brain Volumes and HIV Plasma Markers
Random-effects multivariable linear regressions were performed to evaluate associations between
each of the 8 regional brain volumes and (1) current CD4+ T-cell count or (2) a binary variable
indicating a detectable or undetectable VL (1 or 0, respectively). For each participant, VL was
determined to be detectable according to the detection threshold at the respective collection site,
which varied (range, 19-400 copies/mL) (eTable 4 in the Supplement). To account for differences in
MRI scanner and acquisition, MRI collection site was used as the random-effects grouping variable;
fixed-effects covariates included age, sex, the interaction between age and sex, cART status at the
time of scan (taking or not taking cART), and estimated total intracranial volume to adjust for
variability in head size. Statistical analyses were conducted with the nlme package in R, version 3.2.3
(R Foundation for Statistical Computing). Effect sizes, after accounting for all covariates, were
JAMA Network Open. 2021;4(1):e2031190. doi:10.1001/jamanetworkopen.2020.31190 (Reprinted)
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estimated as d values for dichotomous factors and r values (partial correlation coefficients) for
continuous variables (eMethods and eResults in the Supplement). Bonferroni correction was used to
control the family-wise error rate at 5%; an uncorrected, 2-sided P ⱕ .0063 (.05 divided by 8; ie, the
number of brain regions) was considered statistically significant.
Post Hoc Sensitivity Analyses: Stratification by cART Status and Sex
Post hoc analyses tested for associations between brain volumes and HIV plasma markers when the
data were stratified by (1) cART status and (2) sex. The same analytical framework was used,
removing sex and sex × age interactions from statistical models when stratifying by sex and
removing cART when stratifying by cART status. Group differences in demographic and clinical
factors were evaluated with χ2 tests for dichotomous factors and 2-tailed t tests for continuous
measures.
Validation Analyses Comparing Harmonized Thresholds
Two validation analyses were performed: (1) dichotomizing CD4+ cell count based on the AIDSdefining threshold of 200/μL and (2) defining a common detectable VL (dVL) threshold across sites
(400 copies/mL, the highest site-specific assay detection threshold used across all collection sites).

Results
Demographic and clinical characteristics for participants included from each of the 13 studies after
quality assurance are reported in Table 1 and summarized for the entire ENIGMA-HIV cohort
(N = 1203; mean [SD] age, 45.7 [11.5] years; 880 [73.2%] male; 897 [74.6%] taking cART) in Table 2.
Compared with the 897 participants taking cART and the 880 male participants, 306 participants
not taking cART and 323 female participants were younger, had lower CD4+ cell counts, and were
more likely to have a detectable VL. Proportionally fewer female participants were taking cART at the

Table 2. Summary of Demographic, Clinical, and Neuroanatomical Information Aggregated Across All 13 Participating Studies of HIV-Positive Adults and Stratified
by cART Status and Sexa
cART status

P value for taking
vs not taking
cARTb

Sex
Male
(n = 880)

Female
(n = 323)

<.001

48.3 (10.8)
[20-81]

38.7 (10.6)
[22-70]

<.001

NA

774 (88.0)

123 (38.1)

<.001

<.001

275 (31.8)
[N = 865]

195 (65.9)
[N = 296]

<.001

188 (21.7)
[N = 863]

177 (59.7)
[N = 293]

<.001

Total
(N = 1203)

Taking cART
(n = 897)

Not taking cART
(n = 306)

Age, mean (SD) [range], y

45.7 (11.5)
[20-81]

49.5 (10.0)
[22-81]

34.7 (8.0)
[20-66]

No. (%) taking cART

897 (74.6)

897 (100)

NA

No. (%) with detectable viral load

470 (40.5)
[N = 1161]

201 (22.7)
[N = 884]

269 (97.1)
[N = 277]

No. (%) with viral load >400 copies/mL

363 (31.4)
[N = 1156]

115 (13.0)
[N = 884]

248 (91.1)
[N = 272]

<.001

Variable

+

P value
for male
vs femaleb

CD4 cell count, mean (SD), /μL

447.0 (277.1)

498.9 (278.9)

295.5 (207.3)

<.001

480.2 (276.2)

356.7 (259.3)

<.001

No. (%) with CD4+ cell count <200/μL

230 (19.1)

107 (11.9)

123 (40.2)

<.001

131 (14.9)

99 (30.7)

<.001

Thalamus

7121.3 (995.3)

7256.7 (986.9)

6724.7 (911.6)

<.001

7344.6 (971.8)

6513.1 (782.6)

<.001

Caudate

3595.4 (496.4)

3623.5 (498.6)

3513.1 (481.0)

<.001

3654.4 (495.5)

3434.8 (462.8)

<.001

Putamen

5199.1 (724.5)

5176.2 (754.9)

5266.2 (623.4)

.04

5254.9 (751.7)

5047.2 (620.7)

<.001

Globus pallidus

1541.0 (252.3)

1511.5 (252.2)

1627.6 (232.2)

<.001

1547.2 (255.4)

1524.3 (242.9)

.15

Hippocampus

4049.6 (546.7)

4147.7 (497.5)

3762.2 (582.6)

<.001

4191.1 (504.9)

3664.2 (464.8)

<.001

Amygdala

1549.8 (286.9)

1605.2 (286.2)

1387.5 (219.4)

<.001

1624.8 (274.6)

1345.4 (209.9)

<.001

Accumbens

536.8 (123.9)

524.1 (129.0)

574.2 (98.4)

<.001

534.7 (129.4)

542.7 (107.2)

.28

Lateral ventricles

19 554.4
(12 529.0)

21 331.1
(12 859.3)

14 346.3
(9816.1)

<.001

21 528.3
(12 987.9)

14 176.7
(9264.9)

<.001

Volume, mean (SD), mm3

Abbreviations: cART, combination antiretroviral therapy; NA, not applicable.
a

Subcortical volume comparisons in this table are absolute and were not corrected for
estimated total intracranial volume, as was done in the formal analyses.

b

Differences in dichotomous factors were assessed using χ2 tests; for continuous
measures, differences were assessed using 2-tailed t tests.
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time of MRI. As expected, individuals with a dVL had significantly lower CD4+ cell counts than those
with an undetectable VL (mean [SE] CD4+ cell count in dVL, 336.3/μL [221.5/μL]; mean [SE] CD4+ cell
count in undetectable VL, 532.3/μL [283.1/μL]; P < .001). In addition, as expected, across
participants, older age was associated with smaller volumes of all subcortical structures and larger
ventricular volumes. Results from the age feasibility analysis are presented in eTable 5 and eFigures 1
and 2 in the Supplement. Although we did not have HIV-negative controls, we used the lifespan
centile curves reported in a large, multisite study from the ENIGMA lifespan working group24 and
determined that subcortical volumes of our HIV-positive population did not fall within the same
distribution as those from age-matched healthy individuals (eFigures 3, 4, 5, and 6 and eTable 6 in
the Supplement).

Associations Between Brain Volumes and HIV Plasma Measures
Across all 1203 participants, lower CD4+ cell counts were associated with smaller hippocampal
(r= 0.10; P < .001) (Figure, A and Table 3) and thalamic (r= 0.10; P < .001) volumes and larger
ventricular volumes (r= −0.093; P = .001). A dVL (n = 1161) was associated with smaller hippocampal
volumes (d= −0.17; P = .005) (Figure, B and Table 4). For individual site effects, see eFigures 7 and
8 in the Supplement. As hypothesized, post hoc analyses revealed no lateralized effects in significant
regions (eTable 7 in the Supplement).

Post Hoc Sensitivity Analyses: Stratification by cART Status and Sex
Table 3 details regional CD4+ cell findings within stratified groups. As in the full group, in the subset
of participants taking cART, lower CD4+ cell counts were associated with smaller hippocampal
(r= 0.10; P = .003) and thalamic (r= 0.11; P < .001) volumes and larger ventricular volumes
(r= −0.094; P = .005). However, in participants not taking cART, lower CD4+ cell counts were
associated only with smaller putamen volumes (r= 0.18; P = .002).
Table 4 details regional dVL findings within the stratified groups. The hippocampal associations
detected in the full group were also observed in participants taking cART (d= −0.24; P = .004), along
with smaller amygdala volumes (d= −0.23; P = .004). Only 8 participants not taking cART had an
undetectable VL; therefore, dVL in the group not taking cART was not assessed.
Because participants taking cART were largely male (n = 774 [88.0%]), associations in male
participants mirrored those found in the subgroup taking cART: CD4+ cell counts were associated
with hippocampal (r= 0.12; P < .001), thalamic (r= 0.11; P = .002), and ventricular (r= −0.10;
P = .004) volumes; a dVL was associated with hippocampal (d= −0.22; P = .003) and amygdala
(d= −0.22; P = .003) volumes. Ventricular volume effects (d= 0.20; P = .006) were significant only
in the male subgroup but not the subgroup taking cART. No significant associations between plasma
measures and brain volumes were detected in female participants, although a similar pattern in the
ranking of regional effect sizes was observed between male and female participants for CD4+ cell
count (Pearson r= 0.91; P = .002) (eFigure 9 in the Supplement).

Validation Analyses
Validation analyses largely confirmed primary results. eTables 8 and 9 in the Supplement give the
regional associations with dichotomized CD4+ cell counts (ⱕ200/μL) and a harmonized dVL
threshold (>400 copies/mL).

Discussion
In this cross-sectional study, one of the largest coordinated brain imaging studies of HIV-positive
individuals worldwide, data from 1203 individuals across 6 countries were harmonized and pooled to
find associations between brain volumes and plasma markers used to monitor HIV infection. Brain
volume associations with both CD4+ cell counts and dVL implicated the limbic system, despite the
small effect sizes. Lower CD4+ cell counts were associated with smaller hippocampal and thalamic
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volumes in addition to larger ventricles, and a dVL was also associated with smaller hippocampal
volumes. Sensitivity analyses stratifying the data by cART status revealed that the limbic associations
were in large part attributable to the participants who were taking cART. Stratification also revealed
diverging profiles for regions just shy of statistical significance in the full group. CD4+ cell count
associations with putamen volumes were significant in the group not taking cART. Conversely, in the
participants taking cART, dVL was associated with both hippocampal and amygdala volumes.
Plasma CD4+ T-cell count and VL are routinely assessed in HIV clinics around the world. These
peripheral markers have been correlated with neuropsychological performance in HIV-positive

Figure. Associations Between Subcortical Volumes and CD4+ Cell Count and Detectable Viral Load at the Time of Scan
A Subcortical volumes and CD4+ cell counts
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individuals2,25 as well as postmortem brain tissue VL and pathology.26,27 Unfortunately, the
association between plasma markers and MRI brain volume variation has been inconsistent across
studies. Differences among studies, including clinical and demographic differences, methodologic
variability, and/or insufficient power to estimate robust effect sizes, continue to complicate
understanding of the neuroanatomical and neurofunctional consequences of HIV infection.
Brain signatures that generalize beyond individual studies are important to identify to establish
neuroimaging biomarkers of HIV brain injury. Literature-based meta-analyses assess consistency of
published findings and offer initial insights into the generalizability of HIV-related findings. A recent
such meta-analysis8 of 19 published studies, spanning almost 3 decades, found significantly smaller
total brain volumes and total gray matter volumes in HIV-positive individuals compared with
seronegative controls; however, no significant serostatus associations with the basal ganglia
(caudate, putamen, and globus pallidus) volumes were found. In addition, effect sizes were lower in
more recent studies compared with earlier studies,8 which may suggest a diverging profile of
HIV-affected neurocircuitry in more recent years.
The scope and extent of HIV-related neurocognitive impairment have evolved from the
pre-cART era, and some individuals with chronic HIV in the cART era carry this legacy. For example,

Table 3. Partial Correlation Coefficients (r) and Unstandardized Regression Slopes Reflecting Change in Volume for Every 100/μL Change in CD4+ Cell Count (β)
for Associations Between Regional Brain Volumes and CD4+ Cell Count at the Time of Magnetic Resonance Imaging Across All HIV-Positive Participants
and by cART Status and Sex
Total (n = 1203)
ROI

r

Thalamus

0.10

Caudate

β (SE),
mm3

Taking cART (n = 897)
P value

r

32.24
(8.96)

<.001a

0.11

0.028

4.68
(4.92)

.34

Putamen

0.079

18.83
(6.89)

Globus pallidus

0.075

Hippocampus

β (SE),
mm3

Not taking cART (n = 306)

P value

r

30.08
(8.83)

<.001

0.028

4.14
(5.07)

.0064

0.064

6.44
(2.49)

.01

0.10

16.66
(4.72)

Amygdala

0.075

Accumbens

0.077

Lateral ventricles

−0.093

β (SE),
mm3

Male (n = 880)

P value

r

0.084 39.4
(27.33)

.15

0.11

.41

0.02

4.89
(14.56)

.74

13.89
(7.36)

.06

0.18

57.34
(18.78)

0.076

5.99
(2.67)

.02

0.10

<.001a

0.10

14.68
(4.88)

.003a

5.63
(2.18)

.01

0.079

5.40
(2.29)

.02

2.85
(1.08)

.008

0.075

2.53
(1.14)

.03

−391.50
(122.58)

.001

a

−0.094 −369.8
(132.25)

.005

a

β (SE),
mm3

Female (n = 323)
β (SE),
mm3

P value

r

.002a

0.094

31.61
(19.31)

.10

0.039 6.2
(5.36)

.25

−0.022 −4.24
(10.96)

.70

.003a

0.085 19.57
(7.86)

.01

0.057

13.78
(13.9)

.32

12.03
(6.91)

.08

0.077 6.4
(2.82)

.02

0.048

4.33
(5.14)

.40

0.12

29.18
(14.34)

.04

0.12

<.001a

0.058

10.17
(10.02)

.31

0.04

4.26
(6.18)

.49

0.077 5.5
(2.43)

.02

0.078

6.29
(4.59)

.17

0.11

5.97
(3.15)

.06

0.073 2.66
(1.24)

.03

0.080

3.11
(2.23)

.16

−0.13 −688.14
(314.35)

.03

29.9
(9.66)

18.15
(5.25)

−0.10 −417.5
(142.47)

a

.004

−0.090 −356.96
(226.48)

P value

.12

Abbreviations: cART, combination antiretroviral therapy; ROI, region of interest.
a

Significant at a Bonferroni corrected threshold for tests in 8 ROIs (P ⱕ .0063).

Table 4. Effect Sizes (d) for Associations Between Regional Brain Volumes and Detectable Viral Load at the Time of Magnetic Resonance Imaging Across
All HIV-Positive Participants and by cART Status and Sexa
Total (N = 1161)

Taking cART (n = 884)

Female (n = 296)

d (SE)

P value

d (SE)

P value

d (SE)

P value

d (SE)

P value

Thalamus

−0.12 (0.060)

.046

−0.20 (0.080)

.02

−0.16 (0.073)

.03

−0.015 (0.12)

.90

Caudate

−0.022 (0.060)

.71

−0.044 (0.080)

.59

−0.049 (0.073)

.51

−0.018 (0.12)

.89

Putamen

−0.019 (0.060)

.76

−0.051 (0.080)

.53

−0.048 (0.073)

.52

−0.021 (0.12)

.87

Globus pallidus

−0.015 (0.060)

.80

−0.031 (0.080)

.70

−0.029 (0.073)

.70

−0.057 (0.12)

.66

Hippocampus

−0.17 (0.060)

.005b

−0.24 (0.080)

.004b

−0.22 (0.073)

.003b

−0.12 (0.12)

.33

Amygdala

−0.16 (0.060)

.009

−0.23 (0.080)

.004b

−0.22 (0.073)

.003b

−0.082 (0.12)

.52

Accumbens

−0.12 (0.060)

.06

−0.17 (0.080)

.03

−0.17 (0.073)

.02

0.022 (0.12)

.87

Lateral ventricles

0.16 (0.060)

.0065

0.20 (0.080)

.02

0.20 (0.073)

.0063b

−0.041 (0.12)

.75

Abbreviations: cART, combination antiretroviral therapy; ROI, region of interest.
a

Male (n = 865)

ROI

b

Significant at a Bonferroni-corrected threshold for tests in 8 ROIs (P ⱕ .0063).

We did not assess viral load in those not receiving treatment because of the limited
number of individuals in this subgroup with undetectable viral load (n = 8).
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although the prevalence of neurocognitive deficits may be similar, reports2,28 have highlighted that
learning deficits and poorer mental flexibility were more prominent features in patients treated with
cART compared with patients in the pre-cART era in whom deficits in motor and sustained attention
and psychomotor slowing were more evident. Brain deficits may persist despite cART because of
factors such as possible cART neurotoxicity5,29; irreversible brain damage associated with advanced
disease6,8; reservoirs of ongoing low-grade viral replication and/or persistent immune activation in
the CNS30,31; vascular injury32; and neurodegenerative processes that can occur with aging,33,34
consistent with the hippocampal findings presented here.
In the pre-cART era, HIV-associated dementia was characterized as a subcortical dementia. In
line with reported postmortem neuropathologic and viral protein distributions, neuroimaging studies
of HIV-positive individuals often found smaller basal ganglia volumes,9,10,35-37 in particular smaller
caudate nuclei.11 More recently, neuroimaging findings in HIV-positive individuals have extended
beyond volume differences of the putamen, globus pallidus, nucleus accumbens, and caudate. HIV
serostatus–related differences have been detected to varying degrees in the thalamus,38
amygdala,39 hippocampus,40 and even total gray matter,8 indicating that recent brain alterations
may be more dispersed. These findings may also suggest greater heterogeneity in the causes of brain
injury. Once a staple of reported HIV-related brain alterations, basal ganglia volume associations with
CD4+ cell count or dVL did not survive correction for multiple comparisons in the full group of
HIV-positive participants assessed here but remained significant in the subset not taking cART.
Participants not taking cART were not necessarily cART naive, but their plasma markers may, on
average, be more in line with those recorded before cART initiation. Although the CD4+ cell counts in
this study were associated with altered limbic and not basal ganglia volumes in the full set of
participants, it is possible that in these same individuals, nadir CD4+ cell counts, reflecting a history
of severe immunosuppression before treatment, would be associated with basal ganglia volumes.
The shift in HIV infection from fatal to chronic in the cART era appears to be accompanied by a shift in
the profile of HIV-related brain abnormalities beyond the basal ganglia, frequently implicated in the
pre-cART era, to limbic structures. This shift in subcortical signatures may be contributing to the
increasing range of neuropsychiatric and cognitive outcomes.
In the current study, male study participants may have been more representative of infected
individuals in the cART era: 88.0% of them were taking cART compared with only 38.1% of female
participants, most of whom were recruited from Thailand and South Africa, countries in which a
substantial proportion of individuals eligible for treatment may not receive it. This study found a
similar pattern in the ranking of regional CD4+ cell count effect sizes between sexes but not dVL. As
suggested in a US-based cohort of HIV-positive women,41 demographic and sociocultural factors,
which are themselves associated with many comorbid conditions, potentially mask the effects of HIV
disease. Despite being the largest neuroimaging evaluation of HIV-positive women, the current study
did not detect any significant associations between plasma markers and brain volumes in female
participants alone. This apparent difference in power may be attributable to any number of
confounding factors. For example, comorbidities, including mental health conditions, may play a
confounding role. Female-specific findings were noted in an international study42 in which women
with posttraumatic stress disorder were found to be driving case-control differences in hippocampal
volumes. Trauma, particularly that related to intimate partner violence, is overwhelmingly common
among HIV-positive women,43 so factors such as comorbid posttraumatic stress disorder may be
confounding limbic associations in women. Women constitute 52% of all individuals 15 years and
older living with HIV.44 Nevertheless, women are underrepresented in HIV research, impeding the
reliability and generalizability of findings. Despite evaluating more than 300 HIV-positive women,
twice as many participants included in this study were men; only 2 of the 13 studies had recruited
more than 40% women. A more extensive international effort assessing the neurologic effects of
HIV infection in women is needed.
Effects in limbic structures, as seen here, have been detected in a wide range of clinical
conditions studied in similar large-scale international efforts from the ENIGMA consortium.45 Serious
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mental illnesses, such as depression or substance use disorders, are highly prevalent in HIV-positive
individuals and may increase the risk of HIV transmission.46 Because this study assessed individuals
with and without these comorbidities, limbic associations detected in this study were not likely
simply a reflection of such comorbid neuropsychiatric conditions. However, viral-induced
immunosuppression may also contribute to the risk of developing serious mental illnesses by
targeting the same neurocircuitry implicated across these disorders.
The hippocampus had consistent associations with both CD4+ cell count and VL measures. In
postmortem studies, hippocampal tissue has some of the highest viral concentrations.47
Hippocampal neurons also have increased gliosis and HIV chemokine coreceptors and expression48
and may be particularly susceptible to Tat-induced apoptosis.49 A previous cART-era pathologic
study50 suggests a potential shift in HIV-related inflammation to the hippocampus and surrounding
entorhinal cortex. Hippocampal atrophy is consistently reported across aging populations, and
accelerated atrophy is a hallmark of neurodegenerative diseases, such as Alzheimer disease.
Neuropathologic hallmarks of healthy aging and Alzheimer disease, including elevated levels of
phosphorylated tau and β-amyloid deposits, have been detected in the hippocampus of HIV-positive
individuals taking cART.51,52 Common age- and HIV-related pathologic processes, such as
inflammation and blood-brain barrier impairment, may accelerate age-related neurodegenerative
processes.34 Study participants ranged in age from 20 to 81 years, and although age was associated
with smaller brain volumes, the study did not detect any interactions between age and CD4+ cell
count or dVL in the full group, perhaps because the subgroup taking cART was older than the group
not taking cART. A better understanding of chronic infection in the context of aging remains an
important topic of research.

Limitations
Literature-based meta-analyses provide substantial insights into the reproducibility and consistency
of published findings. However, they are inherently limited by the fact that effects are likely
overestimated because of publication biases, given that studies with null findings are often excluded.
Effect sizes reported in this study are considered small to moderate, yet given the large, diverse
sample, small effect sizes may still be clinically significant. Furthermore, methodologic factors,
including image analysis methods and statistical design, cannot be harmonized in retrospective
analyses. In this study, these limitations were partially addressed by harmonizing image processing
and statistical analyses. Nonetheless, several limitations and challenges remain. The current study
focused only on associations in HIV-positive individuals, without a direct comparison to seronegative
controls. Serostatus comparisons may help elucidate the full extent of HIV-related brain deficits, as
opposed to highlighting regions more selectively affected by the degree of immunosuppression and
viral control. Most of the HIV cohorts included in ENIGMA-HIV at the time of this study recruited only
HIV-positive individuals. Plasma CD4+ cell count and VL were readily available across studies, but
these plasma markers are not comprehensive assessments of the full systemic impact of HIV. Future
efforts are needed to pool and harmonize additional immunologic, cerebrovascular, metabolic, and
inflammatory markers associated with infection. Identifying clinical factors that can be uniformly
collected or interpreted across international studies remains challenging. For example, differences in
treatment regimens with varying CNS penetration effectiveness scores, duration of treatment, and
standards of adherence that qualified a participant categorically as taking cART at the time of MRI
may vary from study to study. Despite such variations, this study identified consistent and robust
brain volume associations with HIV VL and immunosuppression in a large and diverse study sample
of HIV-positive individuals from around the world.

Conclusions
This analysis demonstrates the feasibility and utility of a global collaborative initiative to understand
the neurologic signatures of HIV infection. We invite other HIV researchers to join the ENIGMA-HIV
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consortium. With a greater collaborative effort, we will be able to assess factors that may modulate
neurologic outcomes, including cART treatment regimens, comorbidities, coinfections, substance
use, socioeconomic factors, and demographic factors, as well as the functional implications of such
structural brain differences, in well-powered analyses. Understanding the neurobiological changes
that may contribute to neuropsychiatric and cognitive outcomes in HIV-positive individuals is critical
for identifying individuals at risk for neurologic symptoms, driving novel treatments that may protect
the CNS, and monitoring treatment response.
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